ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
7.65
-0.11 (-1.42%)
Dec 20, 2024, 4:00 PM EST - Market closed
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 6.79M EUR in the half year ending June 30, 2024, with 204.58% growth. This brings the company's revenue in the last twelve months to 9.03M, up 100.87% year-over-year. In the year 2023, ABIVAX Société Anonyme had annual revenue of 4.49M with 0.38% growth.
Revenue (ttm)
9.03M EUR
Revenue Growth
+100.87%
P/S Ratio
n/a
Revenue / Employee
148,049 EUR
Employees
61
Market Cap
465.79M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.49M | 17.00K | 0.38% |
Dec 31, 2022 | 4.48M | 273.00K | 6.50% |
Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
Dec 31, 2019 | -7.00K | -822.00K | -100.86% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Auna S.A. | 1.17B |
Xeris Biopharma Holdings | 187.36M |
Talkspace | 181.29M |
Theravance Biopharma | 63.19M |
Semler Scientific | 58.94M |
Sangamo Therapeutics | 52.29M |
Cartesian Therapeutics | 47.94M |
EyePoint Pharmaceuticals | 45.71M |
ABVX News
- 4 weeks ago - Abivax Establishes an At-the-Market (ATM) Program on Nasdaq - GlobeNewsWire
- 5 weeks ago - Abivax presents third quarter 2024 key financial information - GlobeNewsWire
- 5 weeks ago - Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax - GlobeNewsWire
- 2 months ago - Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewsWire
- 2 months ago - Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease - GlobeNewsWire
- 2 months ago - Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance - GlobeNewsWire
- 3 months ago - Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 - GlobeNewsWire
- 3 months ago - Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model - GlobeNewsWire